Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Radius Health Inc. is Screaming Higher Today

By Brian Feroldi - Feb 22, 2016 at 11:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares are on the move after clinical data released on a competing compound showed that its drug might have a clinical edge.

What: Shares of Radius Health ( RDUS -3.16% ) a biopharmaceutical company focused on developing products that treat osteoporosis and other endocrine-mediated diseases, were up more than 26% as of 10:00 a.m. EST after a competitor reported data from a late-stage clinical trial.

So what: Biotech giant Amgen ( AMGN 1.21% ) and its European partner UCB released data from their Phase 3 FRAME study related to their investigational osteoporosis drug romosozumab. The study showed that romosozumab was able to met its co-primary endpoints as it successfully reduced the incidence of new vertebral fractures in postmenopausal women with osteoporosis in months 12 through 24. The study also showed that women who used the once-a-month injectable experienced a 73% reduction in their risk of developing a spine fracture when compared to patients who took a placebo.

This news caused Radius Health's investors to cheer as the company's experimental osteoporosis drug abaloparatide demonstrated an 86% reduction in the risk of developing a spine fracture when compared to placebo, which might help to give it a slight clinical edge if both drugs find their way to market.

Now what: Shares of Radius Health were mauled in January so I understand why investors are bidding them up so much today based on this news released. With an estimated 2 million osteoporosis-related bone fractures occurring annually in the U.S. alone the market opportunity for abaloparatide looks huge if it can demonstrate clinical superiority over competing drugs. However, even with clinical data on its side its unknown which of these two drugs will ultimately win in the market place -- assuming that both eventually find their way to market -- as Radius Health's abaloparatide requires a daily injection whereas Amgen's romosozumab only has to be administered once-a-month. Will this data be good enough to convince patients and providers that the extra 29 injections a month is worth it?

We won't yet know if either abaloparatide or romosozumab will find their way to market as both drugs have yet to be submitted to the FDA for approval, but both Amgen and Radius have announced plans to have their drugs in regulators hands this year. Radius Health will be releasing its fourth-quarter earnings on Feb. 25, so investors might want to listen in for an updated timeline on a FDA submission.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$211.32 (1.21%) $2.53
Radius Health, Inc. Stock Quote
Radius Health, Inc.
RDUS
$14.38 (-3.16%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.